Fast uptake and long-lasting binding of methamphetamine in the human brain: Comparison with cocaine

NeuroImage

Volumn 43, Issue 4, 2008, Pages 756-763

  Fowler, Joanna S ^a,b,c   Volkow, Nora D ^d,e   Logan, Jean ^a   Alexoff, David ^a   Telang, Frank ^e   Wang, Gene Jack ^a,b   Wong, Christopher ^a   Ma, Yeming ^e   Kriplani, Aarti ^f   Pradhan, Kith ^g   Schlyer, David ^a,f   Jayne, Millard ^e   Hubbard, Barbara ^a   Carter, Pauline ^a   Warner, Donald ^a   King, Payton ^a   Shea, Colleen ^a   Xu, Youwen ^a   Muench, Lisa ^e   Apelskog, Karen ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^f Stony Brook University   (United States)

^g USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE;

ADULT; AFRICAN AMERICAN; ARTICLE; BRAIN CORTEX; BRAIN REGION; CAUCASIAN; COCAINE DEPENDENCE; COMPARATIVE STUDY; CORPUS STRIATUM; HUMAN; HUMAN EXPERIMENT; MALE; NEUROTOXICITY; NORMAL HUMAN; PREVALENCE; PRIORITY JOURNAL; REINFORCEMENT; WHITE MATTER;

ADULT; AFRICAN AMERICANS; BRAIN; CARBON RADIOISOTOPES; COCAINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHAMPHETAMINE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 54449086143     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2008.07.020     Document Type: Article

References (36)

1. Alexoff D.L., Shea C., Fowler J.S., King P., Gatley S.J., Schlyer D.J., and Wolf A.P. Plasma input function determination for PET using a commercial laboratory robot. Nucl. Med. Biol. 22 (1995) 893-904
2. Balster R.L., and Schuster C.R. Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J. Exp. Anal. Behav. 20 (1973) 119-129
3. Barr A.M., Panenka W.J., MacEwan G.W., Thornton A.E., Lang D.J., Honer W.G., and Lecomte T. The need for speed: an update on methamphetamine addiction. J. Psychiatry Neurosci. 31 (2006) 301-313 Review
4. Camp D.M., Browman K.E., and Robinson T.E. The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats. Brain Res. 668 (1994) 180-193
5. Chung A., Lyoo I.K., Kim S.J., Hwang J., Bae S.C., Sung Y.H., Sim M.E., Song I.C., Kim J., Chang K.H., and Renshaw P.F. Decreased frontal white-matter integrity in abstinent methamphetamine abusers. Int. J. Neuropsychopharmacol. 10 (2007) 765-775
6. Cook C.E., Jeffcoat A.R., Hill J.M., Pugh D.E., Patetta P.K., Sadler B.M., et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab. Dispos. 21 (1993) 717-723
7. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 5274-5278
8. Ernst T., Chang L., Leonido-Yee M., and Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54 (2000) 1344-1349
9. Fitzmaurice P.S., Tong J., Yazdanpanah M., Liu P.P., Kalasinsky K.S., and Kish S.J. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J. Pharmacol. Exp. Ther. 319 (2006) 703-709
10. Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., Macgregor R.R., Hitzemann R., Logan J., Bendriem B., Gatley S.J., et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 4 (1989) 371-377
11. Fowler J.S., Kroll C., Ferrieri R., Alexoff D., Logan J., Dewey S.L., Schiffer W., Schlyer D., Carter P., King P., Shea C., Xu Y., Muench L., Benveniste H., Vaska P., and Volkow N.D. PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and (-)-cocaine. J. Nucl. Med. 48 (2007) 1724-1732
12. Fukushima S., Shen H., Hata H., Ohara A., Ohmi K., Ikeda K., Numachi Y., Kobayashi H., Hall F.S., Uhl G.R., and Sora I. Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl) 193 (2007) 55-62
13. Fumagalli F., Gainetdinov R.R., Valenzano K.J., and Caron M.G. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 18 (1998) 4861-4869
14. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., and Caron M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19 (1999) 2424-2431
15. Inoue O., Axelsson S., Lundqvist H., Oreland L., and Långström B. Effect of reserpine on the brain uptake of carbon 11 methamphetamine and its N-propargyl derivative, deprenyl. Eur. J. Nucl. Med. 17 (1990) 121-126
16. Iritani B.J., Hallfors D.D., and Bauer D.J. Crystal methamphetamine use among young adults in the USA. Addiction 102 (2007) 1102-1113
17. Kalasinsky K.S., Bosy T.Z., Schmunk G.A., Reiber G., Anthony R.M., Furukawa Y., Guttman M., and Kish S.J. Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. Forensic. Sci. Int. 116 (2001) 163-169
18. Kuczenski R., Everall I.P., Crews L., Adame A., Grant I., and Masliah E. Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Exp. Neurol. 207 (2007) 42-51
19. 11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 10 (1990) 740-747
20. Newton T.F., Roache J.D., De La Garza II R., Fong T., Wallace C.L., Li S.H., Elkashef A., Chiang N., and Kahn R. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 31 (2006) 1537-1544
21. O'Neil M.L., Kuczenski R., Segal D.S., Cho A.K., Lacan G., and Melega W.P. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge. Synapse 60 (2006) 465-473
22. Rawson R.A., and Condon T.P. Why do we need an addiction supplement focused on methamphetamine?. Addiction 102 Suppl. 1 (2007) 1-4
23. Riviere G.J., Gentry W.B., and Owens S.M. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J. Pharmacol. Exp. Ther. 292 (2000) 1042-1047
24. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., and Partilla J.S. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 (2001) 32-41
25. Segal D.S., Kuczenski R., O'Neil M.L., Melega W.P., and Cho A.K. Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization. Psychopharmacology (Berl) 180 (2005) 501-512
26. Sexton R.L., Carlson R.G., Siegal H.A., Falck R.S., Leukefeld C., and Booth B. Barriers and pathways to diffusion of methamphetamine use among African Americans in the rural South: preliminary ethnographic findings. J. Ethn. Subst. Abuse 4 (2005) 77-103
27. Substance Abuse and Mental Health Services Administration (SAMHSA), 2003 Results from the National Survey on Drug Use and Health: National Findings. Office of Applied Studies, NHSDA Series H-22, DHHS Publication no. SMA 03-3836. Rockville, MD: SAMHSA.
28. Thompson P.M., Hayashi K.M., Simon S.L., Geaga J.A., Hong M.S., Sui Y., Lee J.Y., Toga A.W., Ling W., and London E.D. Structural abnormalities in the brains of human subjects who use methamphetamine. J. Neurosci. 24 (2004) 6028-6036
29. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley J.S., Dewey S., Ashby C., Liebermann J., Hitzemann R., et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry 52 (1995) 456-463
30. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Hitzemann R., Gatley S.J., MacGregor R.R., and Wolf A.P. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology 14 (1996) 159-168
31. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., Vitkun S., Logan J., Gatley S.J., Pappas N., Hitzemann R., and Shea C.E. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386 (1997) 827-830
32. Volkow N.D., Wang G.J., Fischman M.W., Foltin R., Fowler J.S., Franceschi D., Franceschi M., Logan J., Gatley S.J., Wong C., Ding Y.S., Hitzemann R., and Pappas N. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci. 67 (2000) 1507-1515
33. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Wong C., and Logan J. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am. J. Psychiatry 158 (2001) 383-389
34. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Logan J., Wong C., and Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 158 (2001) 377-382
35. Volz T.J., Fleckenstein A.E., and Hanson G.R. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment. Addiction 102 Suppl. 1 (2007) 44-48 Review
36. Weinshenker D., Ferrucci M., Busceti C.L., Biagioni F., Lazzeri G., Liles L.C., Lenzi P., Pasquali L., Murri L., Paparelli A., and Fornai F. Genetic or pharmacological blockade of noradrenaline synthesis enhances the neurochemical, behavioral and toxic effects of methamphetamine. J. Neurochem. 105 (2008) 471-483